# Junta clínica — PT-pseudo_e9fbcdc890f2 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_e9fbcdc890f2",
  "pid": "PT-pseudo_e9fbcdc890f2",
  "task": 1,
  "psa": 82.0,
  "age": 74,
  "months": 2,
  "pirads": "5",
  "psad": 1.281,
  "psav": 9.76,
  "psap": 62.9,
  "vol": 64.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.9339169,
  "medhx": "Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis",
  "meds": "amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN",
  "notes": "PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "96 kg",
    "height": "185 cm",
    "bmi": "28.0",
    "bp": "139/80 mmHg",
    "hr": "72 bpm",
    "smoking": "Ex-smoker (31 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy."
    },
    {
      "s": "History",
      "t": "A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "self-employed contractor (carpentry)",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up"
  ],
  "alcohol": "39 units / week (heavy)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_e9fbcdc890f2
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 82.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 1.281 ng/mL²
  - PSA velocity: 9.76 ng/mL/yr
  - Prior PSA: 62.9 ng/mL
  - Prostate volume: 64.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9339169 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Obesity (BMI >30), Osteoarthritis
  - Current medication: amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 82 ng/mL. PI-RADS 5. PSAD 1.28. Prostate volume 64 mL. csPCa 0.93.

Vitals: weight 96 kg, height 185 cm, BMI 28.0, BP 139/80 mmHg, HR 72 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2023).

Chief complaint: Persistent PSA elevation warrants clinical reassessment after an earlier positive prostate biopsy.

History: A 74-year-old married man residing with his partner works as a self-employed contractor in carpentry. Despite mild osteoarthritis, he maintains a rigorous exercise routine, completing five-kilometre runs three times weekly. His medical background includes hypertension, hypercholesterolaemia, and obesity (BMI >30). Current pharmacotherapy comprises amlodipine, valsartan, atorvastatin, simvastatin, rosuvastatin, and paracetamol PRN. He is an ex-smoker with a cumulative exposure of 31 pack-years, having successfully ceased smoking in 2023. Lower urinary tract symptoms are present, quantified by an IPSS score of 14, though he denies haematuria, skeletal discomfort, or unexplained weight loss. Weekly alcohol intake reaches approximately 39 units. A recent pulmonary function assessment was conducted for routine COPD surveillance. Commuting over an hour by rail, he manages his daily medications independently, relying on his spouse for logistical support.

Physical examination: DRE: The gland presents as symmetrically enlarged, possessing a firm, smooth surface devoid of palpable irregularities or asymmetry. Systemic review remains unremarkable; vital parameters are stable, and examination reveals no peripheral lymphadenopathy or abdominal masses.

Patient info: self-employed contractor (carpentry); Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 39 units / week (heavy); exercise Running 3x/week, 5 km; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.13 epistemic (95% band 0.29-0.82); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 4 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 74 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 82 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 64 mL (1% of my signal; from log_vol, vol) · PSA density = 1.281 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.93 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  decisive   PSA = 82 ng/mL
  important  prior biopsy = Positive
  noted      age = 74 · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · PI-RADS = 5 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — the rule matched the reading urologist in only 5 of 6 labelled cases

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.23: PI-RADS 5, PSA 70.0, PSAD 0.67, age 68, DRE Normal -> DEFER (clear). He wrote: "This patient has PCa and a very high PSA. start treatment and do a PSMA-PET ."
  2. distance 2.08: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 2.08: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.27 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   prior biopsy = Positive · PSA = 82 ng/mL · PI-RADS = 5
  noted      age = 74 · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  decisive   prior biopsy = Positive · PI-RADS = 5
  important  age = 74 · PSA = 82 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 64 mL · PSA density = 1.281 · comorbidity = 4 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
"linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy."
The guideline suggests using the PI-RADS score and PSA density in conjunction with PSA-D categories to guide the decision to perform a biopsy. For this patient, the guideline requires establishing which risk-adapted matrix table applies based on his PI-RADS 5 and PSA density of 1.281 ng/mL².

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is decisive, whereas the guideline treats this as context; the guideline requires the PI-RADS score and PSA density to guide the decision. The guideline suggests that for a PI-RADS 5 and PSA density of 1.281 ng/mL², the decision should be guided by the risk-adapted matrix table. The guideline needs the comparison MRI to determine the appropriate risk-adapted matrix to apply.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: Positive means the guideline suggests that the decision should be guided by the PI-RADS score and PSA density, not solely by the prior biopsy status.
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline requires the PSA trend to be considered alongside the PI-RADS score and PSA density in the risk-adapted matrix.
laboratory_results - the laboratory results: the guideline requires the PSA density value to be used in the risk-adapted matrix to determine the appropriate biopsy strategy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on establishing the comparison status of the lesion in the radiology report and the PSA trend to apply the EAU risk-adapted matrix.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study to guide the biopsy decision.
  psa_trend (get_psa_trend) -> Determine the PSA trend to be considered alongside the PI-RADS score and PSA density in the risk-adapted matrix.
  previous_notes (get_previous_notes) -> Is the grade of the prior biopsy recorded (Gleason or ISUP)? How many biopsy sessions, and when was the last? Is he on a surveillance protocol, and is a confirmatory biopsy due? Is any treatment already agreed or declined?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report need to answer regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend need to answer regarding the PSA trend in the risk-adapted matrix?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion is compared against an earlier study: new.
LESION
Size and zone of the index lesion, as the report words it: "circumscribed, hypointense focus in the right mid-gland peripheral zone spanning 22 x 18 x 15 mm."

psa_trend
The PSA trend to be considered alongside the PI-RADS score and PSA density in the risk-adapted matrix: PSA has risen from 2.0 (Jan 2023) to 82.0 (Feb 2025), showing a significant upward trajectory.

previous_notes
Is the grade of the prior biopsy recorded (Gleason or ISUP)? How many biopsy sessions, and when was the last? Is he on a surveillance protocol, and is a confirmatory biopsy due? Is any treatment already agreed or declined?
Is the grade of the prior biopsy recorded (Gleason or ISUP)? Not recorded. How many biopsy sessions, and when was the last? Not recorded. Is he on a surveillance protocol, and is a confirmatory biopsy due? Not recorded. Is any treatment already agreed or declined?

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the imaging comparison and PSA trend as per the moderator's instruction.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 and PSA density of 1.281 ng/mL² as per the EAU guideline suggests guiding the decision to perform a biopsy.
PSA trend shows a significant upward trajectory, which is a factor to consider in the risk-adapted matrix.

AGAINST sampling this patient now
Prior biopsy status is Positive, which the cohort criterion suggests deferring further tissue sampling if PSA is $\ge 20$ ng/mL.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 82.00 ng/mL over 5 points spanning 25 months; velocity +32.39 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 105.0 ng/mL, conformal 95% band 30.1-365.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 82 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.48
  uncertainty  +/- 0.11 epistemic (95% band 0.26-0.70), of which 0.01 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      PSA = 82 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 64 mL (4% of my signal; from log_vol, vol) · PSA density = 1.281 (0% of my signal; from psad_calc) · comorbidity = 4 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, DRE, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.48  ('discuss' tier, fusion_nolab; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.27  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:DEC E2:—            -> decisive
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:— E2:—                    -> not_used (raised from noted by the board)
  age          74                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:— cohort:not library:not E2:—              -> not_used (raised from noted by the board)
  psa          82 ng/mL                     E1:not E3:not cohort:DEC library:DEC E2:not          -> important
  vol          64 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         1.281                        E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.93                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> decisive
  comorbidity  4 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes) have addressed the moderator's questions. The radiology_report stated the lesion is "new" compared to an earlier study, and the psa_trend showed a significant upward trajectory.

ALIGNMENT WITH THE PANEL
The retrieved evidence supports the PANEL-PROTOCOL's answer of NO BIOPSY. The cohort criterion, which fired the protocol, was based on the PSA being $\ge 20$ ng/mL, which is met by the PSA of 82.0 ng/mL.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report need to answer regarding whether the lesion is compared against an earlier study? Answered by the radiology_report: The lesion is compared against an earlier study: new.
Q2. What does the psa_trend need to answer regarding the PSA trend in the risk-adapted matrix? Answered by the psa_trend: PSA has risen from 2.0 (Jan 2023) to 82.0 (Feb 2025), showing a significant upward trajectory.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 82 ng/mL, because the panel protocol relied on the cohort criterion (PSA $\ge 20$ ng/mL) which was decisive. I would move this to decisive as it was the primary trigger for the protocol.
pirads: decisive: 5, because the panel protocol marked this as decisive, and the EAU guideline explicitly links PI-RADS to the decision matrix.
prior biopsy: decisive: Positive, because the cohort criterion was specifically defined for patients with a tissue diagnosis.
My confidence in the record as it stands is clear, as all required documents were retrieved.

MY SUGGESTION TO THE CHAIR
The panel's position of NO BIOPSY is supported by the cohort criterion firing, which is a rule within the protocol. The rising PSA trend and the new lesion status are noted but do not overturn the protocol's decision based on the retrieved evidence.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Age 74, PSA 82 ng/mL, PI-RADS 5, and prior positive biopsy with unrecorded ISUP grade dictates staging and treatment over further biopsy. The high PSA and known cancer status outweigh the PI-RADS 5 finding. No earlier MRI to compare against is noted.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
